Camille L. Bedrosian Sells 11,442 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille L. Bedrosian sold 11,442 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $3.20, for a total value of $36,614.40. Following the transaction, the insider now directly owns 143,801 shares of the company’s stock, valued at $460,163.20. The sale was disclosed in a filing with the SEC, which is available at this link.

Amylyx Pharmaceuticals Price Performance

Shares of Amylyx Pharmaceuticals stock opened at $2.94 on Friday. The business has a 50 day moving average price of $2.39 and a 200 day moving average price of $2.16. The company has a market capitalization of $199.94 million, a P/E ratio of -2.75 and a beta of -0.55. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). The company had revenue of ($1.02) million for the quarter, compared to analyst estimates of $18.83 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. During the same period in the previous year, the business earned $0.31 EPS. As a group, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several hedge funds have recently modified their holdings of AMLX. AQR Capital Management LLC raised its position in shares of Amylyx Pharmaceuticals by 2,768.0% in the second quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company’s stock valued at $6,348,000 after buying an additional 3,224,454 shares during the last quarter. Almitas Capital LLC acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at $3,617,000. Acadian Asset Management LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $2,300,000. Farallon Capital Management LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 1st quarter worth $3,267,000. Finally, XTX Topco Ltd purchased a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $400,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMLX has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, July 10th. The Goldman Sachs Group increased their target price on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Friday, July 12th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has an average rating of “Hold” and an average target price of $17.60.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.